Vimarsana
Biggest News Aggregation in the World

Page 8 - Commercial Platform News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Commercial Platform. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Commercial Platform Today - Breaking & Trending Today

Athenex to Present at the 39th Annual J.P. Morgan Healthcare Conference - Vimarsana News

Athenex to Present at the 39th Annual J.P. Morgan Healthcare Conference

Press release content from Globe Newswire. The AP news staff was not involved in its creation. Athenex to Present at the 39th Annual J.P. Morgan Healthcare Conference Athenex, Inc.January 5, 2021 GMT BUFFALO, N.Y., Jan. 05, 2021 (GLOBE NEWSWIRE) -- Athenex, Inc., (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, announced that it will participate in the 39th annual J. P. Morgan Healthcare Conference. Johnson Lau, CEO and Board Chairman, and Daniel Lang, Senior...

Source: apnews.com
Athenex Announces FDA Approval of Klisyri® (Tirbanibulin) for the Treatment of Actinic ... - Vimarsana News

Athenex Announces FDA Approval of Klisyri® (Tirbanibulin) for the Treatment of Actinic ...

Press release content from Globe Newswire. The AP news staff was not involved in its creation. Athenex Announces FDA Approval of Klisyri® (Tirbanibulin) for the Treatment of Actinic ... Athenex, Inc.December 15, 2020 GMT Klisyri is the first FDA approved proprietary product for Athenex First-in-class microtubule inhibitor indicated for the topical treatment of actinic keratosis (AK) on the face or scalp with a 5-day application course Klisyri will be manufactured by Athenex Almirall will launch Klisyri in the U.S. in first quarter 2021 BUFFALO, N.Y., Dec. 15, 2020 (GLOBE NEWSWIRE) -- Athenex...

Source: apnews.com
Athenex Announces FDA Approval of Klisyri® (Tirbanibulin) for the Treatment of Actinic Keratosis on the Face or Scalp - Vimarsana News

Athenex Announces FDA Approval of Klisyri® (Tirbanibulin) for the Treatment of Actinic Keratosis on the Face or Scalp

is the first FDA approved proprietary product for Athenex First-in-class microtubule inhibitor indicated for the topical treatment of actinic keratosis (AK) on the face or scalp with a 5-day application course Klisyri will be manufactured by Athenex Almirall will launch Klisyri in the U.S. in first quarter 2021 BUFFALO, N.Y., Dec. 15, 2020 (GLOBE NEWSWIRE) -- Athenex, Inc., (NASDAQ:ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, today announced that the U.S. Food...

Peer to Peer Insurance Market to See Huge Growth by 2025 : Besurance, BitPark, Friendsurance - Vimarsana News

Peer to Peer Insurance Market to See Huge Growth by 2025 : Besurance, BitPark, Friendsurance

  Edison, NJ -- (SBWIRE) -- 12/15/2020 -- Peer to Peer Insurance Market Comprehensive Study is an expert and top to bottom investigation on the momentum condition of the worldwide Peer to Peer Insurance industry with an attention on the Global market. The report gives key insights available status of the Peer to Peer Insurance producers and is an important wellspring of direction and course for organizations and people keen on the business. By and large, the report gives an inside and out understanding of 2020-2025 worldwide Peer to Peer Insurance Market covering extremely significant param...

Source: sbwire.com